CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Semaglutide Pen Injectordrug
Likely dose
Semaglutide Pen Injector 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05302596
NCT05302596Phase 2Completed
CompareCT.gov

Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With GLP-1 Receptor Agonist Treatment

State University of New York at Buffalo·interventional·Posted Mar 31, 2022·Updated Apr 17, 2025

In Brief

A Phase 2 clinical trial evaluating Semaglutide Pen Injector for Obesity and Aging. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This is a single-center, prospective, controlled, randomized and open label study to investigate the effect of the semaglutide addition to standard of care weight loss intervention (personalized lifestyle and exercise) in elderly obese subjects on body weight and body composition as assessed by DEXA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Aging
CountriesUnited States
CollaboratorsNational Center for Advancing Translational Sciences (NCATS)

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMar 31, 2022
Enrollment StartSep 1, 2022
Primary CompletionOct 23, 2023
Study CompletionOct 30, 2024
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 4.3 years ago

Interventions

Semaglutide Pen Injectordrug

semaglutide (up to 1mg) once weekly injection added to the standard of care weight loss program. Semaglutide dose will be started at 0.25 mg dose during the baseline visit and doubled every 2 weeks up to 1mg dose or up to maximum tolerable dose for total of 16 weeks of intervention